Cardarine is most likely cancerous in humans, that's why gsk stopped developing it. The mechanism by which ppar-delta agonists contribute to cancer is understood now and it's as applicable in humans as it is in rodents. The rodent studies were not flawed, by the way, they did exactly what they...